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Abstract
Interleukin 9 (IL-9) has been implicated in mast cell-related inflammatory diseases, such as asthma, where vascular
endothelial growth factor (VEGF) is involved. Here we report that IL-9 (10–20 ng/ml) induces gene expression and secretion
of VEGF from human LAD2. IL-9 does not induce mast cell degranulation or the release of other mediators (IL-1, IL-8, or TNF).
VEGF production in response to IL-9 involves STAT-3 activation. The effect is inhibited (about 80%) by the STAT-3 inhibitor,
Stattic. Gene-expression of IL-9 and IL-9 receptor is significantly increased in lesional skin areas of atopic dermatitis (AD)
patients as compared to normal control skin, while serum IL-9 is not different from controls. These results imply that
functional interactions between IL-9 and mast cells leading to VEGF release contribute to the initiation/propagation of the
pathogenesis of AD, a skin inflammatory disease.
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Introduction
IL-9 was first described in the late 1980s as a member of a
growing number of cytokines that has pleiotropic functions in the
immune system [1]. IL-9 was initially purified and characterized
as a T cell and mast cell growth factor [2]. IL-9 production was
first associated with the Th2 phenotype, and many of the
preliminary functions of IL-9 were tested in models of Th2-
associated immunity [3]. Th17 cells, which are defined by
secretion of IL-17A and IL-17F, may also secrete IL-9 in vitro and
ex vivo [4,5]. Mast cells also produce IL-9 in response to LPS and
IL-1[6,7]. TGF-beta and IL-4, that are secreted by mast cells,
are potent cytokines in promoting the generation of IL-9-
secreting cells [3,8]. One of the main functions of IL-9 is to
promote mast cell growth and function [9]. IL-9, alone or in
combination with stem cell factor or FceRI, promotes the
expression of mast cell proteases and pro-allergic cytokines in
cultured mast cells [10–12].
IL-9 demonstrates pro-inflammatory activity in several mouse
models of inflammation and appears to play a significant role in
the pathogenesis of atopic diseases and asthma [13,14]. Trans-
genic expression of IL-9 in the lung results in allergic inflammation
while blockade of IL-9 decreases allergic inflammation, mastocy-
tosis and airway remodeling [15,16] as well as inflammation [16].
IL-9 and IL-9R expression is increased in lungs of asthmatic
patients, but not healthy controls [13,17]. IL-9 increases
susceptibility to passive or active systemic anaphylaxis [18].
Deficiency in IL-9 or IL-9R attenuates intestinal anaphylaxis,
while transgenic expression of IL-9 in the intestine results in local
mastocytosis and increased susceptibility to intestinal anaphylaxis
[19,20]. Apparently, IL-9 promotes mast cell mediated intestinal
permeability and plays a role in the development of food allergies
[20]. Many patients with moderate atopic dermatitis (AD) were
shown to have high levels of sensitization to foods [21].
IL-9 could be involved in the pathogenesis of inflammatory skin
disorders, such as AD, characterized by chronic skin inflammation
that also involves mast cells [22]. Here we show that IL-9 gene
expression is increased in lesional AD skin and stimulates VEGF
release from cultured mast cells.
Materials and Methods
Reagents
Human IL-9 was purchased from Sigma (St. Louis, MO).
STAT3 inhibitor Stattic was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
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LAD2 mast cells (kindly supplied by Dr. A.S. Kirshenbaum,
National Institutes of Health, Bethesda, MD), derived from a
human mast cell leukemia [23], were cultured in StemPro-34
medium (Invitrogen, Carlsbad, CA) supplemented with 100 U/ml
penicillin/streptomycin and 100 ng/ml recombinant human stem
cell factor (rhSCF, Stemgen, kindly supplied by Swedidh Orphan
Biovitrum AB, (Stockholm, Sweden). Cells were maintained at
37uC in a humidified incubator at 5% CO2.
VEGF release assay
LAD2 cells (16105 cells/250 ml) were distributed in 96-well
microtiter assay plates in triplicate and stimulated in complete
culture medium with the indicated concentrations of IL-9. VEGF
was determined in cell-free supernatants with a commercial
ELISA kit (R&D Systems, Minneapolis, MN) according to the
manufacturer’s directions. VEGF secretion data are expressed as
pg/106 cells. For inhibition studies, inhibitors were added to the
media 30 min prior to stimulation
ELISA analysis of STAT3 phosphorylation
LAD2 cells were plated in 24-well plates (3*103 cells/well) in
complete media. Cells were stimulated with IL-9 for the indicated
time-points. Stimulation was terminated by the addition of ice-cold
PBS. Cells were washed once with PBS and then lysed in cell lysis
buffer (#9803s, Cell Signaling Danvers, MA) and sonicated
briefly. Equal amounts of protein from the cell lysates were used.
Phospho-STAT3 levels were determined in the cell lysates with a
commercial Elisa kit (Cell Signaling) according to the manufac-
turer’s directions.
Patients and biopsies
Full depth (3 mm3) punch skin biopsies were collected from
subjects (patients and controls) who had not received any
medication for 15 days prior to the biopsy and were seen at the
2nd Department of Dermatology of the Attikon General Hospital,
Athens University Medical School, Athens, Greece. The Medical
Ethics Committee of Attikon Hospital Institution’s Human
Investigation Review Board (HIRB) approved this protocol. All
participants gave their written informed consent according to the
Declaration of Helsinki Principles. Patients were free from any
other medical problems. All biopsies (patients and controls) were
obtained from non-exposed skin (back and gluteal) and were
immediately placed in RNAlater solution (Ambion, Inc., Austin,
Texas, USA) and stored at 220uC.
PCR and quantitative PCR
Total RNA from skin biopsies or cultured mast cells was isolated
using Trizol (Invitrogen), according to the manufacturer’s instruc-
tions. Reverse transcription was performed with 200 ng of total
RNA using the iScript cDNA synthesis kit (Ambion, Austin, TX).
In order to measure IL-9, and IL-9 receptor (IL-9r) gene
expression, quantitative real time PCR was performed using
Taqman gene expression assays. The following probes obtained
from Applied Biosystems, were used: IL-9, (ID: Hs00914237_m1);
IL-9 receptor (ID: Hs01108522_m1); Human GAPD (GAPDH)
Endogenous Control (VIC/TAMRA Probe, Primer Limited),
(Number: 4310884E). The cycling conditions consisted of 1 cycle
of 50uC for 2 min, 1 cycle of 95uC for 10 min, 40 cycles of 95uC
for 15 s, 1 cycle of 60uC for 1 min, 1 cycle of 95uC for 15 s, 1 cycle
of 60uC of 30 sec and 1 cycle of 95 for 15 s. Relative mRNA
abundance was determined from standard curves run with each
experiment, and IL-9, and IL-9 receptor expression was
normalized to GAPDH endogenous control.
Results
IL-9 stimulates VEGF production in human mast cells
To examine the effect of IL-9 on VEGF secretion, LAD2 cells
were treated with IL-9 (10, 20 ng/ml) for 48 hr. VEGF mRNA
(measured at 6 hrs) was increased after IL-9 stimulation (Fig. 1A).
IL-9 also stimulated release of VEGF with a maximum of 860 pg/
106 cells at 10 ng/ml, a 2-fold induction (Fig. 1B). There was no
apparent difference between 10 and 20 ng/ml IL-9 and lower
concentrations did not have any effect. There was no degranu-
lation as measured by beta-hexosaminidase release or release of
IL-1, IL-8 or TNF (results not shown).
STAT3 Phosphorylation and activation is involved in IL-9-
induced VEGF release
We investigated downstream events associated with stimulus-
receptor coupling. Stimulation with IL-9 (10 ng/ml) for 5,10, or
20 min, increased STAT3 phosphorylation, which was detected
within 5 min (Fig. 2A). Pretreatment with the inhibitor of the
Figure 1. IL-9 stimulates VEGF production in human mast cells. (A) Gene expression. LAD2 cells were stimulated with IL-9 for 6 hrs, RNA was
extracted and relative VEGF mRNA levels were determined by real-time PCR. (B) Protein release. LAD2 cells were stimulated with the indicated
concentration of IL-9 (10–20 ng/ml) for 48 hrs. VEGF was measured in the supernatant fluid by ELISA. Data are the mean 6 SD of 3 separate
experiments performed in triplicate (*P,0.05 versus unstimulated cells).
doi:10.1371/journal.pone.0033271.g001
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without significantly affecting basal release (Fig. 2B). Together,
these data demonstrate that IL-9 induces phosphorylation of
STAT3 in human mast cells and activation of STAT3 is necessary
for VEGF production.
IL-9 and IL-9 receptor mRNA expression is increased in
skin of patients with AD
Analysis of skin biopsies from AD lesional (n=12) and control
normal skin (n=16) showed that IL-9 (Fig. 3A) IL-9r (Fig. 3B)
gene expression is significantly higher in lesional AD skin than
normal control skin.
IL-9 levels in serum of patients with AD
Serum levels of IL-9 were not different in AD patients as
compared to controls (Fig. 4).
Discussion
We report here for the first time that IL-9 induces VEGF release
from human mast cells. This effect is greater than what has been
previously reported for IL-33 [24]. IL-9 cannot stimulate human
mast cell degranulation on its own or the production of other
cytokines like IL-1, TNF, or IL-8. The amount of IL-9 inducing
maximal VEGF release was 10 ng/ml, while 0.1 and 1 ng/ml had
no effect (results not shown). The concentration we used (10 ng/
ml) may be far highr than the concentrations needed for responses
in some IL-9 dependent cell lines, but less than the dose (20 ng/
ml) used for differentiation of Th17 cells [5], and lower than the
dose (30 ng/ml) shown to stimulate cytokin egene expression from
rodent mast cells [25]. The combination of SP and IL-9 did not
produce any highr release than either trigger alone (results not
shown). Here we also show for the first time that gene expression
of IL-9 and IL-9 receptor are increased in lesional AD skin. In
contrast, Il-9 was not increased in AD patients. A recent paper
investigating serum IL-9 levels in systemic sclerosis, where it was
elevated, also reported no difference between AD levels and
controls [26].
IL-9 is a cytokine produced especially by CD4+ T-cells, but it
appears that mast cells are also capable of producing IL-9 [7]. IL-
9r is mostly expressed on mast cells [27], and also by regulatory T
(TReg) cells, T helper 17 (TH17) cells and antigen-presenting cells
Figure 2. (A) IL-9 induces STAT3 phosphorylation in LAD2 cells. Cells were stimulated with IL-9 for up to 20 min. Phospho-STAT3 levels in the
cell lysates were determined by ELISA. (B) STAT3 inhibitor Stattic inhibits IL-9-induced VEGF release from LAD2 cells. LAD2 cells were pre-incubated
for 30 min with the indicated concentrations of Stattic. Cells were stimulated with IL-9 (10–20 ng/ml) for 24 h and supernatant VEGF was measured
by ELISA. Data are representative of similar experiments.
doi:10.1371/journal.pone.0033271.g002
Figure 3. (A) IL-9 gene expression in the skin of AD affected (n=16) and normal healthy controls (n=12). (B) IL-9 receptor (IL-9r) gene
expression in skin of AD affected (n=19) skin and normal healthy controls (n=20). Relative quantities of mRNA expression were measured by
quantitative RT-PCR and normalized to GAPDH. TaqMan was performed with cDNA reverse transcribed from 100 ng RNA from each sample. *p,0.05.
doi:10.1371/journal.pone.0033271.g003
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[2], it also induces expression of pro-inflammatory cytokines [25],
and release of IL-6 without degranulation and without mast cell
proteases from mouse bone marrow-derived mast cells [29]. IL-9
could also have a synergistic effect with allergic and non-allergic
triggers on activating mast cells and basophils [28]. IL-9 was
recently shown to be involved in the development of food allergies,
conditions known to also implicate mast cells [20].
We also show that the effect of IL-9 on mast cells VEGF release
requires STAT3 activation. It is interesting that STAT6 was
recently shown to be involved in both promotion of Th9
development through distinct transcription factors, activated by
TGF-b and IL-4 [30]. The ability of IL-9 to induce mast cell
release of VEGF is relevant to AD since it was demonstrated that
the levels of dermal angiogenesis correlate with the inflammation
observed in AD mouse models [31]. VEGF levels are also
increased in AD compared to normal skin [32] especially the
VEGF 121 isoform that causes vascular permeability [32,33]. A
recent paper reported that a number of IL-9 and IL-9 r gene
polymorphisms in a Korean population are associated with
increased risk of developing AD [34]. VEGF belongs to a family
of heparin binding growth factors and is a major pro-angiogenic
factor involved in many inflammatory diseases [35]. The
progression of inflammation parallels the dermal angiogenesis in
murine models of atopic dermatitis [31]. The VEGF 121 isoform
also causes vascular permeability [36,37]. Mast cells can secrete
VEGF in response to IgE [38], substance P (SP) [24], and
corticotropin-releasing hormone (CRH) [39], secreted under
stress.
Mast cells are found in large numbers in around blood vessels in
the skin where they participate in allergic and inflammatory
reactions through release of multiple mediators with potent
vasodilatory, inflammatory and nociceptive properties [40]. In
addition to VEGF, histamine increases vascular permeability [41]
and stimulates cutaneous sensory nerves [42] contributing to
pruritus. In acute AD lesions, mast cells are normal in number but
they appear to be degranulated [43]. In chronic lesions, however,
especially in areas of lymphocytic infiltration in the papillary
dermis, mast cells numbers are significantly increased, in close
association with endothelial cells [44,45]. Mast cell activation
levels were shown to be correlated with the severity of AD [46].
Skin mast cells may have important functions as ‘‘sensors’’ of
environmental and emotional stress [47].
The present results is the first indication that interactions
between IL-9 and mast cells may be important in inflammatory
skin diseases [48] where there is increased angiogenesis, such as
AD. They may also represent novel therapeutic targets.
Statistical analysis
Data are expressed as the mean 6 SD. Statistical significance
between experimental samples and controls was calculated using
the Student’s t-test. P,0.05 was considered statistically significant.
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